Abrégé

A brucine gel formulation, a preparation method therefor and use thereof. Said gel formulation comprises 0.5%-1% of brucine, 0.5%-3% of a gel matrix and 10%-30% of a co-solvent. Said brucine hydrogel does not contain a transdermal enhancer, but has an excellent transdermal effect, is easy to coat, has good biosolubility, good skin absorption and good drug film adhesion, and is non-irritating to the skin and mucosa.

Classes IPC  ?

• A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 47/38 - CelluloseSes dérivés

Abrégé

A brucine gel plaster and a preparation method therefor. The brucine gel plaster comprises, calculated by weight percentage, 0.3%-2% of brucine, 3%-10% of a framework material, 20%-50% of a humectant and a co-solvent, 0.1%-2% of a crosslinking agent and a crosslinking regulator, and the balance of water, a backing layer and an anti-sticking layer. The brucine gel plaster uses simple medicinal excipients, does not use a transdermal enhancer, has good skin compatibility, is moisturizing and breathable, is non-irritating to the skin and mucous membranes, has a large drug load, and can be applied repeatedly. The paste is used for treating or ameliorating related diseases requiring anti-inflammation and analgesia such as osteoarthritis, rheumatoid arthritis and rheumatoid arthritis.

Classes IPC  ?

• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61K 47/40 - CyclodextrinesLeurs dérivés
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

A brucine gel formulation, a preparation method therefor and use thereof. Said gel formulation comprises 0.5% - 1% of brucine, 0.5% - 3% of a gel matrix and 10% - 30% of a co-solvent. Said brucine hydrogel does not contain a transdermal enhancer, but has an excellent transdermal effect, is easy to coat, has good biosolubility, good skin absorption and good drug film adhesion, and is non-irritating to the skin and mucosa.

Classes IPC  ?

• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention belongs to the field of medicine and relates to a method for preparing an extract of Strychnos nux-vomica, the method comprising: (1) soaking Strychnos nux-vomica with a first alkaline solution, followed by performing solid-liquid separation to obtain a solid matter; (2) extracting the solid matter obtained in step (1) with ethyl acetate, followed by performing solid-liquid separation to obtain an extraction solution (3) subjecting the extraction solution obtained in step (2) to silica gel column chromatography to obtain an eluate, the eluent being an absolute ethanol or an ethanol solution added with at least one of an ammonia solution, a potassium carbonate solution, a sodium carbonate solution, a sodium bicarbonate solution and potassium bicarbonate solution; (4) drying the eluate to obtain a dried matter; (5) dissolving the dried matter in an acid solution, followed by performing solid-liquid separation to obtain a liquid matter; (6) adjusting the pH value of the liquid matter obtained in step (5) to 8-13, followed by performing solid-liquid separation to obtain a solid matter; and (7) subjecting the solid matter obtained in step (6) to recrystallization. The present invention relates to the extract of Strychnos nux-vomica and a medical use thereof. The extract of Strychnos nux-vomica of the present invention has a high content of brucine and a low content of strychnine, and is safe and effective for use.

Classes IPC  ?

• C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou dans lesquels le système condensé contient au moins quatre hétérocycles
• A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Produits et services

Medicines for human purposes; pharmaceutical preparations; chemico-pharmaceutical preparations; dietetic substances adapted for medical use; tonics [medicines]. Technological research; conducting technical project studies; scientific research; research and development of new products for others; clinical trials; chemical research; cosmetic research; biological research; chemistry services; scientific laboratory services.

Abrégé

A spray-drying method for Pogostemon cablin granular formulation, comprising the following steps: taking a concentrated Pogostemon cablin extractum, adding 2% to 5% of beta-cyclodextrin, mixing uniformly, performing filtration, performing spray drying under conditions of an inlet air temperature of 175 °C to 180 °C and an outlet air temperature of 90 °C to 95 °C and collecting dry powders. The concentrated extractum has a relative density of 1.02 to 1.10 at 60 °C.

Classes IPC  ?

• A61K 36/532 - Agastache, p. ex. hysope
• A61K 9/16 - AgglomérésGranulésMicrobilles

Produits et services

Medicines for human purposes; capsules for medicines; pharmaceutical preparations; chemico-pharmaceutical preparations; suppositories. Technical research; conducting technical project studies; research and development of new products for others; scientific research; quality control; chemical analysis; chemistry services; chemical research; clinical trials.

Produits et services

Medicines for human purposes; pharmaceutical preparations. Clinical trials; chemical research; technical research; scientific research; research and development of new products for others; chemistry services; cosmetic research; scientific laboratory services; conducting technical project studies; biological research.